KURIYEL RALF 4

What Happened Ralf Kuriyel, Senior Vice President of Research & Development at Repligen Corporation (RGEN), received equity compensation on March 5, 2026. The filing reports two awards: 5,284 restricted stock units (RSUs) and 5,669 derivative awards (stock options), both reported as grants (transaction code A) with a reported price/value of $0.00 (standard for compensation grants).

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 23, 2026 (filing appears late relative to the 2-business-day reporting requirement).
• Awards: 5,284 RSUs and 5,669 stock options; reported acquisition price/value $0.00 for each grant.
• Shares owned after the transaction: not specified in the provided filing.
• Footnotes:
  • F1: The 5,284 RSUs vest in equal annual installments over three years starting on the first anniversary of the grant and will be settled only by delivering shares.
  • F2: The 5,669 stock options vest one-third annually on March 5 of 2027, 2028, and 2029.
• Transaction code meaning: A = Award/Grant (compensation), not an open-market purchase or sale.

Context These grants are compensation awards to an executive and do not represent an open-market purchase (which might be viewed as a direct bullish signal) or sale. RSUs convert to shares when vested and delivered; the options become exercisable according to the vesting schedule noted above. The Form 4 was filed well after the transaction date, which is a reporting timeliness issue and could simply reflect administrative delay but is notable to investors.